Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus ETHMOZINE.
DRONEDARONE HYDROCHLORIDE vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to class III. It blocks multiple ion channels (K+, Na+, Ca2+) and exhibits antiadrenergic effects. It prolongs atrial refractory periods and reduces ventricular rate.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
400 mg orally twice daily with meals.
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 13–31 hours) after multiple dosing. Steady state is reached within 4–8 days. The prolonged half-life supports once-daily dosing but requires caution in renal impairment due to accumulation of inactive metabolites.
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Approximately 6% of an oral dose is excreted unchanged in urine. The majority is eliminated as metabolites via biliary excretion into feces (84% of total radioactivity recovered in feces, 6% in urine).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic